TY - JOUR
AU - Montgomery,, Linda
AB - Downloaded from http://journals.lww.com/ebp by BhDMf5ePHKbH4TTImqenVJ2toCr/9wZZjwPUWvYES9lBjFbu9i0DAnSw4JagSjiU on 10/30/2020 were given weight-based ondansetron in doses from A subsequent 2011 meta-analysis of 10 2 to 8 mg orally, noted 1.4 episodes of diarrhea per observational trials (4 cohort, 6 case control) with child in the ondansetron group versus 0.5 per child in more than 1 million patients, which overlapped with the placebo group (P<.001). the meta-analysis above, arrived at similar conclusions regarding overall risk of hip fracture (9 trials, OR 1.3; 95% CI, 1.1–1.4) and spine fracture (4 trials, OR 1.5; Yael Smiley, MS4 David V. Power, MD, MPH 95% CI, 1.2–1.7) in PPI users compared with nonusers. University of Minnesota Medical School This review also examined the risk of wrist/forearm Minneapolis, MN fracture; when compared with nonusers no statistically significant increase was noted with PPI use (3 trials, OR 1. DeCamp LR, et al. Arch Pediatr Adolesc Med. 2008; 162(9):858–865. [STEP 1] 1.1; 95% CI, 0.95–1.2). With respect to duration of PPI 2. Fedorowicz Z, et al. Cochrane Database Syst Rev. 2011; (9):CD005506. [STEP 1] 3. Freedman SB, et al. N Engl J Med. 2006; 354(16):1698–1705. [STEP 2] exposure, only the risk of hip fracture was evaluated and showed a significantly 
TI - Does long-term proton pump inhibitor therapy lead to adverse outcomes?
JF - Evidence-Based Practice
DO - 10.1097/01.EBP.0000540755.97080.f8
DA - 2014-09-01
UR - https://www.deepdyve.com/lp/wolters-kluwer-health/does-long-term-proton-pump-inhibitor-therapy-lead-to-adverse-outcomes-DX4PBji0fQ
SP - 11
VL - 17
IS - 9
DP - DeepDyve
ER -